text.skipToContent text.skipToNavigation
Need help? Please contact us

Summary of Strengths: CAR-NK Cells and Automated Production for Immunotherapy

We have more articles for you

Article overview

The basics of clinical trials

Learn more about the clinical trials: What are they exactly? What types of trials are there? How many phases are there? What happens in each phase?

CAR-T therapy overview

CAR-T therapy is a new cutting edge treatment involving modification of human T cells, but also has some challenges to overcome. Learn more about it in a brief overview of this therapy.

Why we are here

Read a story our Sales Team shared recently that touched our hearts and shows why we love our jobs at Lonza Bioscience.

Interested in our webinars?

Need a break from your daily routine? Grab a coffee and check out our free webinars. 

Subscribe to our eNewsletter

Keep up to speed on the latest scientific developments, events, tips and tools from Lonza.

Knowledge Center

Need technical data?

Browse our Cell and Transfection, Citation, FAQ and Culture Media Technical Databases.

References

Khawar MB, Sun H. CAR-NK Cells: From Natural Basis to Design for Kill. Front Immunol. 2021 Dec 14;12:707542.doi: 10.3389/fimmu.2021.707542. PMID: 34970253; PMCID: PMC8712563.


The information contained herein is believed to be correct. However, no warranty is made, either expressed or implied, regarding its accuracy or the results to be obtained from the use of such information. Lonza disclaims any liability for the use of this presentation and the use of the information contained herein is at your own risk. All trademarks belong to Lonza or its affiliates or to their respective third party owners and are only being used for informational purposes. The products, methods, and processes described in this presentation may be covered by one or more granted patents or pending patent applications. For a complete listing please visit our IP site. ©2023 Lonza. All rights reserved.